About Ultimovacs

Ultimovacs is a small pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. UV1 is a synthetic peptide vaccine.
The peptides included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.

The company is currently performing three clinical trials with UV1. Two trials are documenting safety and the vaccines ability to activate the immune system against cancer cells expressing the hTERT fragments that are the components of the vaccine when given as a single treatment.

A third clinical trial is assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma.

Ultimovacs is owned by Gjelsten Holding, The Norwegian Radium Hospital Research FoundationInven2 ,Canica AS and Sundt AS. The company is currently located in Oslo Science Park, Oslo, Norway, but will move to Oslo Cancer Cluster Innovation Park in July 2015. The company is an active member of Oslo Cancer Cluster.

Management

Board of Directors